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Introduction 
Multiple system atrophy (MSA) is a sporadic, adult-onset, progressive neurodegenerative disease 
characterized clinically by parkinsonism, cerebellar ataxia, autonomic failure, and corticospinal 
signs with poor or absent response to levodopa, and pathologically by cell loss, gliosis, and glial 
cytoplasmic inclusions in several neural cell systems (striatonigral, olivopontocerebellar, 
autonomic) [1]. Bladder dysfunction, and in males erectile dysfunction, usually are the first 
symptoms of the disease. The presenting motor symptoms can be of parkinsonian type with 
bradykinesia, rigidity, and gait instability or of cerebellar type with ataxia. Indeed, the clinical terms 
MSA-P and MSA-C were introduced to classify cases according to the predominant motor disorder 
(parkinsonian or cerebellar). MSA is considered a synucleinopathy along with Parkinson’s disease 
(PD) and dementia with Lewy bodies (LBD) [2]. Diagnostic categories of possible, probable and 
definite MSA were introduced, with a diagnosis of definite MSA requiring neuropathological 
confirmation [1].  
The analysis of cognitive functions in MSA has gained interest. Nevertheless the related profile and 
degree of cognitive impairment is still debated. Indeed, the presence of dementia, particularly at 
onset, is an exclusion feature by current consensus criteria [1,3]. To our knowledge, there is only 
one study on the longitudinal evolution of cognitive functions in MSA [4]. We therefore 
investigated cognitive functions longitudinally in a group of probable MSA patients, matching data 
with sleep parameters.  
 
Review on cognitive impairment in MSA 
Cognitive deficits  
Heterogeneous cognitive dysfunctions in MSA have been reported by many authors [4-29]. The 
executive functions are described as the most frequent impaired abilities but other cognitive 
domains can be involved as memory, visuospatial, and constructional functions. Brown et al [6] in a 
large cohort of MSA patients found that approximately two-thirds of subjects showed no significant 
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cognitive impairment. Impairment in a single domain was found in 28.6%, while impairment in two 
or more domains was present in 13.5% and significant cognitive impairment was observed in 11-
32% of patients. Cognitive impairment was predicted by greater motor disability, fewer than 10 
years of education, male gender, and presence of cardiovascular dysautonomia. It is however 
noteworthy that in the cognitive impaired group of patients, the diagnosis was further pathologically 
confirmed in 64.4% of cases while a final diagnosis of progressive supranuclear palsy, LBD or 
amyotrophic lateral sclerosis was ascertained in the other ones. In the unimpaired group, diagnosis 
of multiple system atrophy was confirmed in 94.6% of cases.  
Wenning et al [30] in a pathologically confirmed case study, showed that dementia was detected in 
a 15.7% of a sample of 38 MSA cases and in none of them dementia was reported within the first 5 
years onset. In another study [31], 14% of a sample of 83 pathologically confirmed cases were 
identified as demented.  
 
Evolution of cognitive deficits 
To our knowledge, only one study [4] analyzed the longitudinal evolution of cognitive functions in 
a group of 14 patients affected by striatonigral degeneration-type of MSA (SND), according to 
Quinn’s criteria [32]. At first evaluation, MSA patients showed a significant deficit in a test of 
verbal fluency if compared with a group of patients affected by PD. After a mean of 21 months 
follow-up, patients did significantly worse on a visual search test. No patients were clearly 
demented at either evaluation. 
 
Difference of cognitive deficits between MSA-P and -C 
Kawai et al [13] compared 21 MSA-P with 14 MSA-C patients. In respect to controls, MSA-P 
patients showed involvement of visuospatial and constructional function, verbal fluency, and 
executive functions while MSA-C patients were impaired only in visuospatial and constructional 
functions with a milder degree of involvement compared with MSA-P patients. These data suggest 
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a more severe and widespread impairment in MSA-P patients, despite similar disease duration. 
Other studies [11,16,26] obtained heterogeneous and even conflicting data. Bak et al [16], in fact, 
found no visuospatial impairment in a group of MSA patients that included subjects with long 
disease duration, high levels of physical disability, and evidence of other cognitive domain 
impairment. These data are consistent with those of Robbins et al [26] on a group of MSA-P 
patients and with those of Bürk et al [15] on a MSA-C sample that did not show any visuospatial 
functions impairment. On the contrary, Kao et al [11] confirmed the presence of visuospatial 
deficits in a group of MSA patients. 
 
Neuropsychiatric symptoms 
Kao et al [11] described depression in the 50% of patients of a small group of MSA subjects, 
anxiety in the 33.3% and disinhibition in 10%. Schrag et al [8] confirmed these data while Kawai et 
al [13] and Brown et al [6] found a smaller prevalence of depression (about 21-22%) and Chang et 
al [12] confirmed a significantly presence of anxiety in a group of MSA-C patients. Balas et al [7] 
made also the analysis of the impact effect of mood, anxiety and depression, on cognitive functions 
of a MSA group of subjects compared with controls and a group of patients affected by PD. The 
comparison of depression and anxiety levels showed that the MSA-P and PD patients reported 
significantly greater state anxiety, trait anxiety, and depression than controls as well as MSA-C 
patients reported a significantly increased state anxiety compared to controls. Authors conclude that 
anxiety and depression are related to cognitive decline. 
 
Pathogenetic mechanisms of cognitive deficits  
The pathogenetic mechanisms of cognitive deficits in MSA are debated. When compared with 
others parkinsonian syndromes, MSA patients display a milder degree of cognitive impairment 
respect to corticobasal degeneration (CBD), progressive sopranuclear palsy (PSP) and LBD. In 
respect to PD without dementia, not definite differences seem emerge [4,6,11,16-19,24-26]. 
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A SPECT study by Kaway et al [13] shows that frontal lobe involvement can be responsible for 
cognitive dysfunction in patients with MSA. Hypoperfusion in the medial frontal cortices and 
dorsolateral prefrontal cortex is detected in MSA-P patients and the severity of cognitive 
impairment is correlated with the hypoperfusion in the dorsolateral prefrontal cortex. Frontal 
cortical atrophy has been also detected bilaterally in MSA-C by means of a voxel-base 
morphometry study together with bilateral cerebellum gray matter reduction [12]. This suggests that 
cognitive tasks in patients with MSA-C are influenced by various lesions: cerebellum, 
cerebellocortical circuits, and the frontal lobe. Complex interactions between frontal cortex and 
basal ganglia have to be considered influencing cognitive performances in MSA. Lyoo et al [14], 
analyzing the progression of MSA by PET examination, found that hypometabolism started from 
the frontal and cerebellar regions, sparing the basal ganglion in a group of patients with a shorter 
disease duration (less than one year). Patients with longer disease duration showed hypometabolism 
in more widespread cerebral cortical areas involving the frontal, temporal, parietal and cingulate 
cortices. Patients with shorter disease duration had executive and verbal memory dysfunctions, 
while patients with longer disease duration had multiple domain cognitive impairment, including 
visuospatial deficits. Furthermore, comparing functional with morphologic data of these patients, 
the authors suppose that the hypometabolism observed is more likely caused by the widespread and 
distribution of glial cytoplasmatic inclusions than by cortical loss, especially in the first phases of 
the disease. An alternative hypothesis could be the progressive alteration of the afferent cortical 
inputs arising from the subcortical nuclei (e.g. locus coeruleus and substantia nigra), thus linking 
together subcortical and cortical structures. Finally, the influence of orthostatic hypotension on 
cognitive function in MSA is still controversial [9,33-35].  
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Review on sleep disturbances in MSA 
Sleep related complaints 
A clinical questionnaire based study by Ghorayeb et al [36] showed that 70% of MSA patients 
complains of sleep disorders compared to 51% of patients with PD. Sleep fragmentation is reported 
by 53% of patients as the most frequent complaint followed by early waking (33%) and insomnia 
(20%). Excessive daytime sleepiness has been also referred by Ghorayeb et al [37] in half of MSA 
patients while Moreno-Lopez et al [38] has recently reported it in 28% of patients with MSA, 
weakly correlated with disease severity and not correlated with the amount of dopaminergic 
treatment. Sleep-disordered breathing and sleep efficiency predict excessive daytime sleepiness in 
MSA [38]. 
 
Sleep structure 
Polysomnographic studies reported total sleep time and sleep efficiency reduced and wake after 
sleep onset increased [39-43]. Plazzi et al [42] found sleep stage percentages unchanged as a whole 
group of patients but individual variations were described. Vetrugno et al [40] found stages 1 and 2 
increased, 3 and 4 decreased while REM sleep was normal. On the contrary, in a study by Nam et al 
[39], designed to eliminate the major confounding variables of sleep such as obstructive sleep 
apneas (OSA) and periodic limb movements during sleep (PLMS) and the influence of anti-
parkinsonian medications, no alteration of the stage distribution of sleep was found. These authors 
conclude that MSA by itself does not affect the sleep structure since even the analysis of the 
microstructure (i.e. sleep instability) compared with controls shows no differences in every aspect, 
including CAP rate, CAPs A and B, and non-CAP. However, this topic is a matter of debate since 
Vetrugno et al [44] had shown in a group of MSA patients a significantly lower CAP rate compared 
to a group of patients with primary restless legs syndrome.  
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Sleep-related respiratory abnormalities  
Nocturnal stridor and OSA as the most common sleep-related breathing disorders in MSA patients 
have been extensively reported [36,37,40,42,43]. The prevalence of nocturnal stridor (a strained, 
high-pitched, harsh respiratory sound) varies from 13% to 69% [45,46]. In one study, stridor was 
more frequently detected in MSA-C than in MSA-P patients [40], but the contrary was also shown 
[37]. OSA ranges from 15% to 37% [40-42] and may contribute to mild O2 desaturation occurring 
during sleep in MSA. The relationship between nocturnal respiratory abnormalities and cognitive 
performance in MSA has not been specifically investigated yet. 
 
Periodic limb movements (PLMS) 
PLMS are frequently reported in polysomnographic studies on MSA [39-42,44]. They are 
significantly increased respect to control [41,42,44], and may contribute to sleep fragmentation and 
reduced sleep efficiency. Restless legs syndrome, a condition often correlated with PLMS, in a 
questionnaire based study, occurred in 28% of patients with MSA, doubling the frequency occurred 
in PD patients (14%) and 4 times more frequent than in the control group (7%) and unrelated to the 
amount of dopaminergic treatment [38]. 
 
REM sleep behavior disorder (RBD) 
REM sleep behavior disorder, a REM sleep parasomnia, is the most common sleep-related disorder 
in MSA [36,37, 40,42,47,48] and may precede the development of parkinsonism by years 
[42,49,50]. Indeed, up to 81% of patients with idiopathic RBD develop a parkinsonian disorder 
[51]. Ninety to 100% of MSA patients have polysomnographic confirmed RBD and clinical 
symptoms of RBD precede the onset of MSA by plus than 1 year in 44% of the patients evaluated 
[40,42]. 
Comparing clinical and video-polysomnographic characteristics of idiopathic RBD vs the RBD 
seen in MSA and PD, Iranzo et al [52] showed that patients with MSA, compared to subjects with 
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PD, had a significantly shorter duration of disease, a higher REM sleep without atonia percentage, a 
greater PLMS index, and less total sleep time. Furthermore, subjects with MSA, compared to those 
with idiopathic RBD, had an onset of RBD at a younger age, were less likely to be aware of their 
abnormal sleep behaviours, had reduced total sleep time, and higher PLMS index. Authors suggest 
that in MSA there could be a more severe dysfunction in the structures that modulate REM sleep. 
This hypothesis could also explain the natural evolution of RBD in MSA. Indeed, Vetrugno et al 
[47] analyzed RBD in two MSA patients showing its evolution in a more complex and pervasive 
sleep disturbance with possible associated confused arousals and hallucinations. In these patients 
sleep quality and quantity severely decreased and the sleep pattern gradually disrupted, with stages 
no longer identifiable (the so-called Status Dissociatus). Authors hypothesize that this condition 
may be due to the progressive degeneration of the neuronal structure responsible for the origin of 
the RBD, in agreement with findings by Iranzo et al [52]. Furthermore, they remarked that these 
two patients did not develop any global intellectual decline suggestive of dementia.  
 
General aspects on RBD and related cognitive deficits 
Cognitive deficits in idiopathic RBD have been reported [53,54]. Neuropsychological data in 34 
patients with idiopathic RBD showed deficits of short- and long-term verbal visual memory in 
about 40% patients and 25% of these patients were also impaired on executive functions or verbal 
associative fluency [53]. Ferini-Strambi et al [54], in a longitudinal healthy controls matched study, 
disclosed visuospatial constructional dysfunction and altered visuospatial learning in idiopathic 
RBD. These neuropsychological deficits were not correlated to RBD duration or to selected video-
polysomnography data such as sleep efficiency, stage 3 and 4 NREM and REM sleep percentages, 
and PLMS index. Since in LBD there is evidence of perceptual dysfunctions, i.e. 
visuoconstructional and visuospatial deficits [55-57], Authors suggest idiopathic RBD as a possible 
early marker of LBD. Indeed, in a group of 37 patients with RBD affected by degenerative 
dementia, Boeve et al found that 34 met clinical criteria for possible or probable LBD [58]. This 
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hypothesis was recently confirmed based on the neuropsychological pattern similarity between 
idiopathic RBD and LBD detected in a selected group of RBD patients matched with a group of 
healthy controls [59]. Finally, in a recent prospective study, RBD confers a 2.2-fold increased risk 
of developing Mild Cognitive Impairment (MCI) within 4 years [60] and in this population MCI 
patients convert to dementia at twice the rate of those without [60]. Summarizing, clinicopathologic 
data show that patients with RBD and MCI, regardless of the MCI subtype, are likely to evolve a 
LBD [49,59,61-64]. 
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Prospective study 
 
Patients and Methods 
Consecutive patients, fulfilling criteria for probable MSA [1], were evaluated in our Neurological 
Department from January 2009 to June 2011. Patients with significant current or previous 
neurological or psychiatric comorbidity likely to confound the test results (history of strokes, severe 
depression, active psychosis), alcoholism or other substance abuse, use of neuroleptics or other 
antipsychotics and tricyclic antidepressants and advanced disease causing significant physical 
debility (making cooperation for neuropsychological testing difficult) were excluded. Low doses of 
selective serotonin reuptake inhibitors antidepressants or dopaminoagonists/levodopa were allowed.  
Ten patients responding to inclusion/exclusion criteria were enrolled. All subjects gave their 
informed consent to the study according to the Declaration of Helsinki. 
All patients underwent a detailed interview, checked with interviews of close relatives, and a 
general and neurological examination, including application of the UMSARS for assessing disease 
severity [65]. Patients were also investigated by blood tests (haemachrome, thyroid function, 
vitamin B12, folates, cholesterol, triglycerides, syphilis serology), by MRI scans to exclude space 
occupying and neoplastic lesions or major atrophic and vascular lesions, according to exclusion 
criteria, and by means of a cardiovascular reflexes study. An extensive battery of 
neuropsychological tests exploring different cognitive functions was administered and video-
polysomnographic recording acquired.  
All patients were revaluated (T1) a mean of 16±5 (range: 12-28) months after the initial evaluation 
(T0). At the second evaluation (T1), the neuropsychological assessment and video-
polysomnography were repeated. 
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Neuropsychological and affective evaluation  
The tests and scales employed are standardized in the Italian population and listed in Table 1. These 
tests were standardized for age, years of education and sex in the Italian population [66-75]. We 
evaluated global cognition by Mini Mental Status Examination (MMSE) [76,77], and Brief Mental 
Deterioration Battery (BMDB) [78-81]. BMDB consists of verbal and visuospatial tasks which are 
scored using a method of equivalent points. Pathological tasks are those in which the subject’s 
performance is below the lower limit of the tolerance interval of 95% for a confidence level of 95%. 
BMDB is derived from Mental Deterioration Battery [82] by discriminant function analysis’s 
procedures, allowing inclusion of the smallest tasks with the highest correct classification and with 
a Final Result allowing a classification for each subject with respect to the threshold value of zero 
with negative scores considered as pathological. We also investigated learning, verbal, visual, 
spatial memory, attention, language, constructional praxis, visuospatial and executive functions, 
abstract and concrete thinking (Table 1). We evaluated depression with the Beck Depression 
Inventory (BDI) [83] and anxiety by the State-Trait Anxiety Inventory—Form Y (STAI) [84]. 
 
Video-polysomnographic recording 
Patients underwent an all-night video-polysomnography (VPSG) which included EEG (C3-A2, O2-
A1, Cz-A1), right and left EOG, surface EMG from submental, right and left extensor carpi radialis 
and tibialis anterior and intercostalis muscles, microphone, oro-nasal airflow, thoracic and 
abdominal respirogram, ECG, systemic arterial blood pressure by means of Finapress and 
oxyhaemoglobin saturation (SaO2). Sleep was scored according to American Academy of Sleep 
Medicine (AASM) criteria [85].  
The tonic and phasic components of REM sleep were scored separately, according to AAMS 
criteria. Each 30-second epoch was arbitrarily defined as tonic if tonic chin EMG activity was 
present for more than 50% of the epoch. Phasic EMG REM activity was evaluated for mini-epochs 
of 3 seconds; a phasic EMG event was defined as any burst of EMG activity lasting 0.1-5.0 seconds 
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in duration with an amplitude exceeding and at least 4 times the background EMG activity. Each 
30-second epoch of REM sleep was defined as phasic if at least 5 mini-epochs (50% of the epoch) 
contain bursts of transient muscle activity. 
The arousal index (number of arousals per hour of sleep), apnoea–hypopnoea index (number of 
obstructive/central/mixed apneas/hypopneas per hour of sleep) and PLMS index (number of PLM 
per hour of sleep), were evaluated for each patients according to AASM criteria. RBD, defined 
according to International Classification of Sleep Disorders [86], was checked against the video 
recordings. 
 
Statistical analysis 
Data were analyzed using the SPSS statistical analysis software, version 18.0. We performed a 
descriptive analysis of the various parameters of patients. Considering that some variables were 
non-normally distributed, statistical analysis was done with non-parametric tests (Wilcoxon test for 
correlated samples). Cognitive performances were correlated with both clinical variables and 
polygraphic data using Pearson’s correlation and non-parametric Kendal Tau correlation.    
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Results 
Seven men and 3 women were enrolled. Six had probable cerebellar type MSA (MSA-C) (4 men) 
and four had probable parkinsonian type MSA (MSA-P) (3 men). The mean age was 57.8±6.4 years 
(range: 47-64) with a mean age at disease onset of 53.2±7.1 years (range: 43-61) and symptoms 
duration at T0 of 60±48 months (range: 12-144) (Table 2).   
 
Neuropsychological findings 
At the initial evaluation (T0), 7 patients showed no cognitive deficits while 2 patients (MSA-C) had 
a long term verbal memory deficit and 1 patient (MSA-P) had deficits in constructional praxis and 
visuospatial functions (Table 3). Considering global cognitive indexes for each patient (MMSE and 
BMDB Final Result) and daily living activities, no patient could be stated demented. At T0, mean 
values of all tests in the whole group were within normal range while mean values of scales for 
depression and trait anxiety scales were slightly increased (Table 4). Nevertheless, none of the 
patients had major depression, according to DSM IV criteria.  
At the second evaluation (T1), after a mean of 16±5 months (range: 12-28) after T0, 6 patients still 
showed no cognitive deficits, 3 patients were cognitive unchanged, respectively showing deficits in 
long term verbal memory in 2 (MSA-C) and in constructional praxis and visuospatial functions in 
1(MSA-P). Only 1 patient (MSA-P) worsened developing multiple cognitive deficits (long term 
verbal memory; short term spatial memory; attention; constructional praxis; language; visuospatial 
functions; abstract thinking) from a non impaired cognitive condition. In this patient, global 
cognitive indexes (MMSE and BMDB Final Result) were still unchanged and within normal limits. 
At T1, mean values of all tests in the whole group were still within normal range. Slightly increased 
mean values of scales for depression, state and trait anxiety were confirmed. 
Comparisons between neuropsychological and affective evaluation at T1 and T0 showed a 
significant worsening in two tests of attention: Barrage Test (score) (p = 0.02) and Trail Making 
Test (A) (p = 0.01). A comparison (T1/T0) between motor performances and functional autonomy 
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scales disclosed a significant worsening in IADL (p= 0.01) and UMSARS (p = 0.005). No 
significant correlation was found between the neuropsychological results and clinical variables (e.g. 
symptoms duration, MSA type). 
 
Findings on VPSG 
No significant differences were found between T1 and T0 VPSG parameters. No significant 
correlation was found between the neuropsychological results and VPSG findings or RBD duration. 
In particular: 
Sleep structure: Sleep efficiency was reduced (n.v. > 85%) and REM latency increased (n.v. 60-90 
min) (Table 5). Sleep structure was characterized by a slight increase of NREM sleep stages 1-2 
(n.v. 45-55%). 
Sleep related complaints: 80% of patients complained about sleep fragmentation at T0 and T1. 
Excessive daytime sleepiness was not referred by patients as assessed by Epworth Sleepiness Scale 
[87]. 
Respiratory abnormalities: snoring was detected in 3/10 patients and paradoxical breathing in 
6/10. Only in 2 patients the apnea index was higher than 10 compatible with a diagnosis of OSAS 
and 1 of these displayed nocturnal stridor. Stridor was detected in 7/10 patients. For the whole 
group of patients, mean SaO2 throughout sleep remained at 93%, with the lowest mean values at 
89%. 
PLMS: PLMS were present in all patients with abnormal PLMS index in 9/10 patients (n.v. ≥10).  
RBD: All patients referred a history compatible with RBD that preceded the onset of the disease in 
6/10 patients (range: -3,-1 years, respect the onset of the disease), coincided with the onset in 2 and 
followed in 2 (4 and 7 years after the onset). All patients showed continuous EMG activity and 
repetitive motor unit potential discharges in the submental mylohyoideus muscle while awake and 
during sleep, with phasic or tonic increase during REM sleep. RBD in the form of complex motor 
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behaviours such as limb and body jerks or complex vigorous movements was recorded in 9/10 
patients. 
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Discussion  
Neuropsychological findings  
At first evaluation, the majority of our patients had not any cognitive deficits while only three had 
selective cognitive deficits (two patients in long-term verbal memory and one in visuo-spatial 
tasks). Our findings are consistent with those of the majority of previous reported ones [4-30]. 
Considering the follow-up of our patients, after a mean of 16 months, the above mentioned three 
patients were unchanged, whereas one of the seven previously not impaired ones developed non 
amnesic multiple cognitive deficits. In this last patient, the global cognitive indexes were still within 
normal limits, therefore this patient should not be considered as demented. Moreover, the clinical 
problem of the majority of MSA patients is related with the severe motor disability that could 
induce a bias in attempting to judge the impact of functional autonomies on daily living. 
The majority of our patients (80%) disclosed a mild degree of depression and anxiety, confirming 
the prevalence of known data [8,11]. Depression and anxiety were present in all four patients with 
isolated cognitive deficits, without a difference in respect to the type of MSA (P or C). In our study, 
we did not find relevant differences in cognitive performance between MSA-P and MSA-C patients, 
although some authors signalized a greater degree of cognitive deficits in MSA-P patients [13].  
Soliveri et al [4], analyzing the evolution of cognitive functions in a group of MSA patients, 
disclosed a verbal fluency deficit and a significant worsening on a visual search test. No patients 
were clearly demented at either evaluation. In our study, a significant worsening was found in two 
tests exploring attention (Barrage Test and Trail Making Test-A) while global cognitive indexes 
showed no significant difference. Although Barrage Test and Trail Making Test mainly explore 
attention, other cognitive functions such as ability to inhibit contrasting responses, speed of 
cognitive processing and visual searching capacity are implied. However, it’s noteworthy that 
results at the Wisconsin Card Sorting Test (WCST) were within normal limits in all our patients at 
either evaluations, except for the patient who developed multiple deficits at the second evaluation. 
WCST explores mainly the cognitive flexibility that is an aspect of executive functions and is 
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frequently altered in PD and parkinsonian syndromes [15,17]. Thus, it’s conceivable that a selected 
deficit of attention may occur in a minority of MSA patients, especially along the evolution of the 
disease, probably as an expression of a functional cognitive impairment of frontal type. Indeed, 
cerebral SPECT and PET studies in MSA have shown that hypometabolism is observable in frontal 
lobes, even in the first phases of the disease [13,14]. Frontal lobes hypometabolism is thought to be 
the consequence of both cortical and subcortical atrophy and their associated cortical 
pathophysiological changes. Lyoo et al [14] suggest that these functional changes could be the 
consequence of the spread and distribution of glial cytoplasmatic inclusions and related neuronal 
cortical loss and/or the consequence of the alteration of the afferent cortical inputs arising from the 
subcortical nuclei (e.g. locus coeruleus and substantia nigra). This last pathogenetic hypothesis 
could explain the complex relations that occur in MSA between the progressive degeneration of 
cortical-subcortical anatomical structures, the pattern and evolution of the deficits of cognitive 
functions and the possible subtle alterations of sleep. In fact, in MSA, subcortical anatomical 
structures, especially brainstem nuclei, are firstly altered leading to a functional modification of the 
afferent cortical inputs that could impair attention and execution. Subsequently, after some years, 
cognitive functions may worsen, probably as a consequence of a widespread of cortical glial 
cytoplasmatic inclusions and related neuronal loss. Moreover, it’s noteworthy that RBD, as an early 
modification of sleep that may precede the onset of the disease by years, is significantly related to 
anatomical alterations of subcortical nuclei of the brainstem, especially locus coeruleus [63]. 
 
Sleep structure, sleep-related respiratory abnormalities and PLMS 
Polygraphic data of our patients confirm a mild alteration of sleep structure, with sleep efficiency 
reduced, slight increase of the NREM stages, and increase of REM latency without significant 
difference between the first and the second polygraphic recording. Our patients show a frequency of 
stridor and OSA comparable with those previous reported, respectively of 70% and 20%, with a 
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mild O2 desaturation [40-42,45,46]. PLMS are significantly increased as reported in literature [40-
42,44], and may probably contribute to sleep fragmentation, reducing its efficiency.  
 
RBD and related cognitive deficits 
RBD was present in all our patients and preceded the onset of the disease in 6 (3 MSA-C and 3 
MSA-P). Of this last group, 4 patients showed or developed isolated cognitive deficits. In idiopathic 
RBD, visuoconstructional and visuospatial deficits had been detected with a pattern similar to the 
neuropsychological profile of LBD [54,58,59]. In our sample, visuoconstructional and visuospatial 
deficits were detected in two patients while the other two patients showed a long-term verbal 
memory deficit. So, all our patients with isolated cognitive deficits had a RBD that preceded the 
onset of the disease of a few years but a homogeneous neuropsychological pattern was not detected. 
Moreover, as in Ferini Strambi et al [54], neuropsychological deficits did not correlate to RBD 
duration or to selected VPSG data. 
Idiopathic RBD confers a 2.2-fold increased risk of developing MCI within 4 years [60]. In our 
sample, the patient who developed multiple cognitive deficits from a normal condition after about 
three years of disease had RBD that started one year before the onset of the disease. In the other 
three patients who showed stable cognitive deficits, RBD started few years before the onset of the 
disease. Moreover, cognitive deficits were not found in the remaining two patients with RBD that 
preceded the onset of the disease. So, even if a correlation between neuropsychological deficits and 
RBD duration was not found, the majority of our patients (4/6) with a RBD onset prior the 
beginning of the disease showed isolated cognitive deficits. Probably, statistical correlation was not 
evidenced as a result of a small sample size. A follow-up of our patients should allow a more 
detailed characterization of their cognitive evolution; nevertheless the dramatic worsening of motor 
and dysautonomic functions make very difficult, if not impossible, performing formal 
neuropsychological assessment. 
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Conclusions 
The majority of our patients affected by MSA do not show any cognitive deficits at the first 
neuropsychological evaluation neither at the follow-up, while isolated cognitive deficits (verbal 
memory, visuospatial functions and constructional praxis) are present in the remaining patients. 
Attention is the cognitive function which significantly worsened after a mean of 16 months follow-
up. Our data confirm the previous findings concerning the prevalence, type and the evolution of 
cognitive deficits in MSA. Regarding the developing of a condition of dementia, our data did not 
show a clear-cut diagnosis of dementia.  We confirmed mild alteration of sleep structure and 
frequency of stridor, OSA and PLMS. In our MSA patients, we found that RBD duration does not 
correlate with neuropsychological findings. 
20 
 
References 
 
1. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, 
Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi 
K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 
71:670-676 
2. Wenning GK, Geser F, Stampfer-Kountchev M, Tison F (2003) Multiple system atrophy: an update. Mov Disord 
18 Suppl 6:S34-42 
3. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, 
Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK (1999) Consensus statement on the 
diagnosis of multiple system atrophy. J Neurol Sci 163:94-98 
4. Soliveri P, Monza D, Paridi D, Carella F, Genitrini S, Testa D, Girotti F (2000) Neuropsychological follow up in 
patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive 
supranuclear palsy. J Neurol Neurosurg Psychiatry 69:313-318 
5. Spaccavento S, Del Prete M, Loverre A, Craca A, Nardulli R (2012) Multiple system atrophy with early cognitive 
deficits: A case report. Neurocase. doi:10.1080/13554794.2012.713494 
6. Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, 
Payan C, Leigh NP; NNIPPS Study Group (2010) Cognitive impairment in patients with multiple system atrophy 
and progressive supranuclear palsy. Brain 133:2382-2393 
7. Balas M, Balash Y, Giladi N, Gurevich T (2010) Cognition in multiple system atrophy: neuropsychological profile 
and interaction with mood. J Neural Transm 117:369-375 
8. Schrag A, Sheikh S, Quinn NP, Lees AJ, Selai C, Mathias C, Litvan I, Lang AE, Bower JH, Burn DJ, Low P, 
Jahanshahi M (2010) A comparison of depression, anxiety, and health status in patients with progressive 
supranuclear palsy and multiple system atrophy. Mov Disord 25:1077-1081 
9. Kawamura K, Shimohata T, Nakayama H, Tomita M, Ozawa T, Nishizawa M (2010) Factors influencing the 
cognitive function in patients with multiple system atrophy. Mov Disord 25:2891-2892 
10. Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K (2009) Assessment of dementia in patients with multiple 
system atrophy. Eur J Neurol 16:589-594 
11. Kao AW, Racine CA, Quitania LC, Kramer JH, Christine CW, Miller BL (2009) Cognitive and neuropsychiatric 
profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. 
Alzheimer Dis Assoc Disord 23:365-370 
21 
 
12. Chang CC, Chang YY, Chang WN, Lee YC, Wang YL, Lui CC, Huang CW, Liu WL (2009) Cognitive deficits in 
multiple system atrophy correlate with frontal atrophy and disease duration. Eur J Neurol 16:1144-1150 
13. Kawai Y, Suenaga M, Takeda A, Ito M, Watanabe H, Tanaka F, Kato K, Fukatsu H, Naganawa S, Kato T, Ito K, 
Sobue G (2008) Cognitive impairments in multiple system atrophy: MSA-C vs MSA-P. Neurology 70:1390-1396 
14. Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH, Rinne JO, Lee MS (2008) Effects of disease duration on 
the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain 
131:438-446 
15. Bürk K, Daum I, Rüb U (2006) Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord 
21:772-776 
16. Bak TH, Caine D, Hearn VC, Hodges JR (2006) Visuospatial functions in atypical parkinsonian syndromes. J 
Neurol Neurosurg Psychiatry 77:454-456 
17. Krishnan S, Mathuranath PS, Sarma S, Kishore A (2006) Neuropsychological functions in progressive supranuclear 
palsy, multiple system atrophy and Parkinson's disease. Neurol India 54:268-272 
18. Bak TH, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR (2005) Subcortical dementia revisited: similarities 
and differences in cognitive function between progressive supranuclear palsy (PSP), corticobasal degeneration 
(CBD) and multiple system atrophy (MSA). Neurocase 11:268-273 
19. Bak TH, Rogers TT, Crawford LM, Hearn VC, Mathuranath PS, Hodges JR (2005) Cognitive bedside assessment 
in atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 76:420-422 
20. Paviour DC, Winterburn D, Simmonds S, Burgess G, Wilkinson L, Fox NC, Lees AJ, Jahanshahi M (2005) Can the 
frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal 
neuropsychological testing. Neurocase 11:274-282 
21. Lange KW, Tucha O, Alders GL, Preier M, Csoti I, Merz B, Mark G, Herting B, Fornadi F, Reichmann H, 
Vieregge P, Reiners K, Becker G, Naumann M (2003) Differentiation of parkinsonian syndromes according to 
differences in executive functions. J Neural Transm 110:983-995 
22. Berent S, Giordani B, Gilman S, Trask CL, Little RJ, Johanns JR, Junck L, Kluin KJ, Heumann M, Koeppe RA 
(2002) Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and 
hereditary olivopontocerebellar atrophy. Brain Cogn 50:194-206 
23. Monza D, Soliveri P, Radice D, Fetoni V, Testa D, Caffarra P, Caraceni T, Girotti F (1998) Cognitive dysfunction 
and impaired organization of complex motility in degenerative parkinsonian syndromes. Arch Neurol 55:372-378 
24. Meco G, Gasparini M, Doricchi F (1996) Attentional functions in multiple system atrophy and Parkinson's disease. 
J Neurol Neurosurg Psychiatry 60:393-398 
22 
 
25. Pillon B, Gouider-Khouja N, Deweer B, Vidailhet M, Malapani C, Dubois B, Agid Y (1995) Neuropsychological 
pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. J 
Neurol Neurosurg Psychiatry 58:174-179 
26. Robbins TW, James M, Owen AM, Lange KW, Lees AJ, Leigh PN, Marsden CD, Quinn NP, Summers BA (1994) 
Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests 
sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 57:79-88 
27. Robbins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD (1992) Cognitive performance in multiple 
system atrophy. Brain 115:271-291 
28. Testa D, Fetoni V, Soliveri P, Musicco M, Palazzini E, Girotti F (1993) Cognitive and motor performance in 
multiple system atrophy and Parkinson's disease compared. Neuropsychologia 31:207-210 
29. Sullivan EV, De La Paz R, Zipursky RB, Pfefferbaum A (1991) Neuropsychological deficits accompanying 
striatonigral degeneration. J Clin Exp Neuropsychol 13:773-788 
30. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP (2000) What clinical features are most 
useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 
68:434-440 
31. O'Sullivan SS, Massey LA, Williams DR, Silveira-Moriyama L, Kempster PA, Holton JL, Revesz T, Lees AJ 
(2008) Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131:1362-1372 
32. Quinn N (1989) Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 20:78-89 
33. Poda R, Guaraldi P, Solieri L, Calandra-Buonaura G, Marano G, Gallassi R, Cortelli P (2012) Standing worsens 
cognitive functions in patients with neurogenic orthostatic hypotension. Neurol Sci 33:469-473 
34. Peralta C, Stampfer-Kountchev M, Karner E, Köllensperger M, Geser F, Wolf E, Seppi K, Benke T, Poewe W, 
Wenning GK (2007) Orthostatic hypotension and attention in Parkinson's disease with and without dementia. J 
Neural Transm 114:585-588 
35. Allcock LM, Kenny RA, Mosimann UP, Tordoff S, Wesnes KA, Hildreth AJ, Burn DJ (2006) Orthostatic 
hypotension in Parkinson's disease: association with cognitive decline? Int J Geriatr Psychiatry 21:778-783 
36. Ghorayeb I, Yekhlef F, Chrysostome V, Balestre E, Bioulac B, Tison F (2002). Sleep disorders and their 
determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry 72:798-800 
37. Ghorayeb I, Bioulac B, Tison F (2005) Sleep disorders in multiple system atrophy. J Neural Transm 112:1669-
1675 
38. Moreno-López C, Santamaría J, Salamero M, Del Sorbo F, Albanese A, Pellecchia MT, Barone P, Overeem S, 
Bloem B, Aarden W, Canesi M, Antonini A, Duerr S, Wenning GK, Poewe W, Rubino A, Meco G, Schneider SA, 
23 
 
Bhatia KP, Djaldetti R, Coelho M, Sampaio C, Cochen V, Hellriegel H, Deuschl G, Colosimo C, Marsili L, Gasser 
T, Tolosa E (2011) Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol 
68:223-230 
39. Nam H, Hong YH, Kwon HM, Cho J (2009) Does multiple system atrophy itself affect sleep structure? Neurologist 
15:274-276 
40. Vetrugno R, Provini F, Cortelli P, Plazzi G, Lotti EM, Pierangeli G, Canali C, Montagna P (2004) Sleep disorders 
in multiple system atrophy: a correlative video-polysomnographic study. Sleep Med 5:21-30 
41. Wetter TC, Collado-Seidel V, Pollmächer T, Yassouridis A, Trenkwalder C (2000) Sleep and periodic leg 
movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 23:361-367 
42. Plazzi G, Corsini R, Provini F, Pierangeli G, Martinelli P, Montagna P, Lugaresi E, Cortelli P (1997) REM sleep 
behavior disorders in multiple system atrophy. Neurology 48:1094-1097 
43. Manni R, Morini R, Martignoni E, Pacchetti C, Micieli G, Tartara A (1993) Nocturnal sleep in multisystem atrophy 
with autonomic failure: polygraphic findings in ten patients. J Neurol 240:249-250 
44. Vetrugno R, D'Angelo R, Cortelli P, Plazzi G, Vignatelli L, Montagna P (2007) Impaired cortical and autonomic 
arousal during sleep in multiple system atrophy. Clin Neurophysiol 118:2512-2518 
45. Yamaguchi M, Arai K, Asahina M, Hattori T (2003) Laryngeal stridor in multiple system atrophy. Eur Neurol 
49:154-159 
46. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP (1997) Multiple system atrophy: a review of 203 
pathologically proven cases. Mov Disord 12:133-147 
47. Vetrugno R, Alessandria M, D'Angelo R, Plazzi G, Provini F, Cortelli P, Montagna P (2009) Status dissociatus 
evolving from REM sleep behaviour disorder in multiple system atrophy. Sleep Med 10:247-252 
48. Tachibana N, Kimura K, Kitajima K, Shinde A, Kimura J, Shibasaki H (1997) REM sleep motor dysfunction in 
multiple system atrophy: with special emphasis on sleep talk as its early clinical manifestation. J Neurol Neurosurg 
Psychiatry 63:678-681 
49. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF (2010) REM sleep behavior 
disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 75:494-499 
50. Tison F, Wenning GK, Quinn NP, Smith SJ (1995) REM sleep behaviour disorder as the presenting symptom of 
multiple system atrophy. J Neurol Neurosurg Psychiatry 58:379-380 
51. Schenck CH, Boeve BF, Mahowald MW (2013) Delayed emergence of a parkinsonian disorder or dementia in 81% 
of older males initially diagnosed with idiopathic REM sleep behavior disorder (RBD): 16year update on a 
previously reported series. Sleep Med. doi: 10.1016/j.sleep.2012.10.009  
24 
 
52. Iranzo A, Santamaría J, Rye DB, Valldeoriola F, Martí MJ, Muñoz E, Vilaseca I, Tolosa E (2005) Characteristics 
of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 65:247-252 
53. Cox S, Risse G, Hawkins J, Shenck C, Mahowald M (1990) Neuropsychological data in 34 patients with REM 
sleep behavior disorder (RBD). Sleep Res 19:206 
54. Ferini-Strambi L, Di Gioia MR, Castronovo V, Oldani A, Zucconi M, Cappa SF (2004) Neuropsychological 
assessment in idiopathic REM sleep behavior disorder (RBD): does the idiopathic form of RBD really exist? 
Neurology 62:41-45 
55. Mori E, Shimomura T, Fujimori M, Hirono N, Imamura T, Hashimoto M, Tanimukai S, Kazui H, Hanihara T 
(2000) Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol 57:489-493 
56. Shimomura T, Mori E, Yamashita H, Imamura T, Hirono N, Hashimoto M, Tanimukai S, Kazui H, Hanihara T 
(1998) Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neurol 55:1547-1552 
57. Walker Z, Allen RL, Shergill S, Katona CL (1997) Neuropsychological performance in Lewy body dementia and 
Alzheimer's disease. Br J Psychiatry 170:156-158 
58. Boeve BF, Silber MH, Ferman TJ, Kokmen E, Smith GE, Ivnik RJ, Parisi JE, Olson EJ, Petersen RC (1998) REM 
sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 
51:363-370 
59. Terzaghi M, Sinforiani E, Zucchella C, Zambrelli E, Pasotti C, Rustioni V, Manni R (2008) Cognitive performance 
in REM sleep behaviour disorder: a possible early marker of neurodegenerative disease? Sleep Med 9:343-351 
60. Boot BP, Boeve BF, Roberts RO, Ferman TJ, Geda YE, Pankratz VS, Ivnik RJ, Smith GE, McDade E, 
Christianson TJ, Knopman DS, Tangalos EG, Silber MH, Petersen RC (2012) Probable rapid eye movement sleep 
behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study. 
Ann Neurol 71:49-56 
61. Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, Wszolek Z, Graff-Radford NR, Uitti R, Van 
Gerpen J, Pao W, Knopman D, Pankratz VS, Kantarci  K, Boot B, Parisi JE, Dugger BN, Fujishiro H, Petersen RC, 
Dickson DW (2011) Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. 
Neurology 77:875-882 
62. Boeve BF (2010) REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior 
disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y 
Acad Sci 1184:15-54 
63. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, Benarroch EE, Ahlskog JE, Smith GE, 
Caselli RC, Tippman-Peikert M, Olson EJ, Lin SC, Young T, Wszolek Z, Schenck CH, Mahowald MW, Castillo 
25 
 
PR, Del Tredici K, Braak H (2007) Pathophysiology of REM sleep behaviour disorder and relevance to 
neurodegenerative disease. Brain 130:2770-2788 
64. Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldeoriola F, Tolosa E (2006) Rapid-eye-
movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. 
Lancet Neurol 5:572-577 
65. Wenning GK, Tison F, Seppi K, Sampaio C, Diem A, Yekhlef F, Ghorayeb I, Ory F, Galitzky M, Scaravilli T, Bozi 
M, Colosimo C, Gilman S, Shults CW, Quinn NP, Rascol O, Poewe W; Multiple System Atrophy Study Group 
(2004) Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 
19:1391-1402 
66. Ferracuti S, Cannoni E, Sacco R, Hufty AM (2007) Contributi per un assessment Neuropsicologico. Manuale 
Clinico. Giunti Organizzazioni Speciali, Firenze 
67. Colombo L, Sartori G, Brivio C (2002) Stima del quoziente intellettivo tramite l’applicazione del TIB (Test di 
Intelligenza Breve). Giornale Italiano di Psicologia 3:613-638 
68. Caffarra P, Vezzadini G, Dieci F et al (2002) Una versione abbreviata del test di Stroop: dati normativi nella 
popolazione italiana. Nuova Rivista di Neurologia 12:111–115 
69. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Rey-Osterrieth complex figure: normative values in 
an Italian population sample. Neurol Sci 22:443-447 
70. Laiacona M, Inzaghi MG, De Tanti A, Capitani E (2000) Wisconsin card sorting test: a new global score, with 
Italian norms, and its relationship with the Weigl sorting test. Neurol Sci 21:279-291 
71. Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E (1996) Trail making test: 
normative values from 287 normal adult controls. Ital J Neurol Sci 17:305-309 
72. Spinnler H, Tognoni G (1987) Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci  
6(Suppl.8):1–120 
73. Orsini A, Grossi D, Capitani E, Laiacona M, Papagno C, Vallar G (1987) Verbal and spatial immediate memory 
span: normative data from 1355 adults and 1112 children. Ital J Neurol Sci 8:539-548 
74. Novelli G, Papagno C, Capitani E et al (1986) Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti 
normali. Archivio di Psicologia, Neurologia e Psichiatria 47:279–296 
75. De Renzi E, Faglioni P, Ruggerini C (1977) Prove di memoria verbale d’impiego clinico per la diagnosi di 
amnesia. Archivio di Psicologia, Neurologia e Psichiatria 3:303–318 
76. Folstein MF, Folstein SE, McHugh PR (1975) ‘Mini Mental State’: a practical method for grading the cognitive 
state of patients for the clinician. J Psychiatr Res 12:189–198 
26 
 
77. Measso G, Cavarzeran F, Zappala` G et al (1993) The Mini-Mental State Examination: normative study of an 
Italian random sample. Dev Neuropsychol 9:77–85 
78. Gallassi R, Oppi F, Poda R, Scortichini S, Stanzani Maserati M, Marano G, Sambati L (2010) Are subjective 
cognitive complaints a risk factor for dementia? Neurol Sci 31:327-336 
79. Gallassi R, Bisulli A, Oppi F, Poda R, Di Felice C (2008) Subjective cognitive complaints, neuropsychological 
performance, affective and behavioural symptoms in non-demented patients. Int J Geriatr Psychiatry 23:95-101 
80. Gallassi R, Morreale A, Di Sarro R, Lorusso S (2002) Value of clinical data and neuropsychological measures in 
probable Alzheimer’s disease. Arch Gerontol Geriatr 34:123–134 
81. Gallassi R, Lenzi P, Stracciari A, Lorusso S, Ciardulli C, Morreale A, Mussuto V (1986) Neuropsychological 
assessment of mental deterioration: purpose of a brief battery and a probabilistic definition of ‘normality’ and ‘non-
normality’. Acta Psychiatr Scan 75:62–67 
82. Carlesimo GA, Caltagirone C, Gainotti G (1996) The Mental Deterioration Battery: normative data, diagnostic 
reliability and qualitative analyses of cognitive impairment. Eur Neurol 36:378–384 
83. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen 
Psychiatry 45:561–571 
84. Spielberger CD, Vagg PR, Barker LR et al (1980) The factor structure of the State-Trait Anxiety Inventory. In:  
Sarason IG, Spielberger CD (eds) Stress and Anxiety. Hemisphere/Wiley, New York 
85. Iber C, Ancoli-Israel S, Chesson A, Quan SF (2007) The AASM manual for the scoring of sleep and associated 
events: rules, terminology and technical specifications. IL: American Academy of Sleep Medicine, Westchester  
86. International Classification of Sleep Disorders. Diagnostic & Coding Manual (2005), 2nd ed. IL: American 
Academy of Sleep Medicine, Westchester 
87. Vignatelli L, Plazzi G, Barbato A, Ferini-Strambi L, Manni R, Pompei F, D'Alessandro R; GINSEN (Gruppo 
Italiano Narcolessia Studio Epidemiologico Nazionale) (2003) Italian version of the Epworth sleepiness scale: 
external validity. Neurol Sci 23:295-300 
27 
 
Tables 
 
Table 1. Neuropsychological tests and assessment of anxiety and depression 
Cognitive Functions Test 
  
Global cognitive functions indices MMSE (range:0–30) (Folstein et al, 1975), MMSE corrected for age and education 
(range:1.93–35.24; cut-off: <23.8) (Measso et al, 1993) 
 
Brief Mental Deterioration Battery (BBDM) with Final Result (FR) (cut-off: <0) 
(Gallassi et al, 1986, 2002) 
 
Memory Rey’s 15 Words: immediate recall (range:0–75; cut-off: <28.53); delayed recall 
(range:0–15; cut-off:<4.69) (Carlesimo et al, 1996) 
 
Paired-associated Word Learning Test (range:0–22.5; cut-off: <8.73) (De Renzi et al, 
1977) 
 Immediate Visual Memory (range:0–22; cut-off: <13.85) (Carlesimo et al, 1996) 
 Digit Span Forward (range:0-9; cut-off: <3.75) (Orsini et al, 1987) 
 
Corsi Block-tapping Test (range:0-infinite; cut-off: <3.75) (Spinnler and Tognoni, 
1987) 
 
Rey-Osterrieth Complex Figure Test: delayed recall (range:0-36; cut-off: <6.20) 
(Caffarra et al, 2002) 
 
Attention Barrage Test (time cut-off: ≥90; score cut-off: ≤9; errors cut-off: ≥2; result cut-off: 
>2.5) (Gallassi et al, 1986, 2002) 
 Stroop Test (time cut-off: >27.5; errors cut-off: >7.5) (Caffarra et al, 2002) 
 
Trail Making Test (A cut-off: >93; B cut-off: >283; B-A cut-off: >187) (Giovagnoli et 
al, 1996) 
 
Language Verbal Fluency: phonemic  (range:0–infinite; cut-off: <17.35) (Carlesimo et al, 1996); 
semantic  (range:0–infinite; cut-off: <25) (Novelli et al, 1986) 
 
Constructional praxis Copy Design: simple (range:0–12; cut-off: <7.18) (Carlesimo et al, 1996) 
 
Rey-Osterrieth Complex Figure Test: direct copy (range:0-36; cut-off: <28) (Caffarra 
et al, 2002) 
 
Visuospatial functions Judgment of Line Orientation Test (range:0-30; cut-off: <19) (Ferracuti et al, 2000) 
 
Executive functions Wisconsin Card Sorting Test (global score cut-off: <90.50; perseverations cut-off: 
<42.60; non-perseverative errors cut-off: <29.90; failure to maintain the set cut off: 
<3) (Laiacona et al, 2000) 
 
Abstract/concrete thinking - 
Intelligence 
Raven Coloured Progressive Matrices (range:0–36; cut-off: <18.96) (Carlesimo et al, 
1996) 
 Analogies (range:0–20; cut-off: <15.1) (Gallassi et al, 1986; 2002) 
 
Test di Intelligenza Breve derived from the National Adult Reading Test by Nelson 
H.E., 1982 (raw score cut-off: ≥19.8; total IQ cut-off: ≤93.1) (Colombo et al, 2002) 
 
Anxiety State and Trait Anxiety Inventory–Y (range:20–80; cut-off: >50 T points) (Spielberger 
et al, 1980) 
 
Depression Beck Depression Inventory (range:0–63; cut-off: >9) (Beck et al, 1961) 
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Table 2. Clinical data  
Sex (m/f) 7/3 
Age (years, mean±s.d.) 57.8±6.4 (47-64) 
Education (years, mean±s.d.) 10.7±4.5 (5-17) 
Age at onset (years, mean±s.d.) 53.2±7.1 (43-61) 
Symptoms duration at T0 (months, 
mean±s.d.) 60±48 (12-144) 
MSA type (C/P) 6/4 
RBD (n. of patients) 10/10 
RBD age at onset (years, mean±s.d.) 53.4±7.3 (40-61) 
 
 
Table 3. Neuropshycological findings: T0/T1evolution  
Patient/sex 
Age at 
examination  
(years) 
(T0/T1)  
Educatio
n (years) 
MSA 
type 
(C/P) 
Symptoms 
duration (years) 
(T0/T1)  
Impaired cognitive functions  
(T0/T1) 
      
1/f 52/54 8 C 2/4 T0/T1: Long term verbal memory 
2/m 59/60 5 P 2/3 
T0: No deficit 
T1: Long term verbal memory; Short term 
spatial memory; Attention; Constructional 
praxis; Language; Visuospatial functions; 
Abstract thinking; Executive functions. 
3/m 47/50 13 C 2/4 T0/T1: Long term verbal memory 
4/m 64/65 8 P 2/3 T0/T1: No deficit 
5/m 62/63 13 C 13/15 T0/T1: No deficit 
6/m 48/49 13 C 6/7 T0/T1: No deficit 
7/m 62/63 17 P 1/2 T0/T1: No deficit 
8/f 63/64 5 P 5/6 T0/T1: Constructional praxis; Visuospatial functions 
9/m 58/59 17 C 12/13 T0/T1: No deficit 
10/f 64/65 8 C 4/5 T0/T1: No deficit 
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Table 4. Neuropsychological, affective and functional evaluation 
Neuropsychological, affective and functional tests and 
scales 
 
I evaluation (T0) 
(mean±s.d.) 
 
 
II evaluation (T1) 
(mean±s.d.) 
 
   
MMSE 28.1±2.07 28.26±1.73 
Brief Mental Deterioration Battery Final Result 2.23±0.93 2.46±1.02 
Rey’s 15 Words   
    immediate recall 45.4±10.64 47.42±10.28 
    delayed recall 9.08±3.06 9.82±3.59 
Barrage Test    
    time 56.4±24.2 61±32.5 
    score  12.2±1.03 10.4±1.77* 
    errors 0.1±0.31 0.3±0.67 
    result -0.22±0.88 0.3±1.82 
Copy Design simple 11.17±1.04 9.8±2.89 
Immediate Visual Memory 20.3±2.03 20.8±1.29 
Analogies 18.4±1.32 18.6±2.02 
Verbal Fluency   
    phonemic   30.29±8.05 26.12±7.35 
    semantic   48.1±6.38 44.2±7.33 
Stroop Test   
    time 16.16±7.4 23.34±28.03 
    errors -0.4±0.68 0.28±1.5 
Rey-Osterrieth Complex Figure Test   
    direct copy 33.3±6.38 29.42±9.71 
    delayed recall 17.67±3.97 16.57±5.63 
Digit Span Forward 6.28±1.18 6.18±1.08 
Corsi Block-tapping Test 5.96±1.04 5.56±1.19 
Trail Making Test    
    A  35.5±17.87 60.75±43.82* 
    B 62.45±48.17 93.15±76.7 
    B-A 27±41.04 31.85±35.85 
Paired-associated Word Learning Test 13.22±5.65 12.7±4.37 
Judgment of Line Orientation Test 26±5.22 25.30±4.99 
Raven Coloured Progressive Matrices 31.16±4.19 31.40±5.14 
Test di Intelligenza Breve   
    IQ verbal 107.2±9.5 107.2±9.5 
    IQ performance 109.6±8.55 109.6±8.55 
    IQ global 108.7±9.63 108.7±9.63 
Wisconsin Card Sorting Test   
    perseverations 5.3±8.32 1.67±4.9 
    non-perseverative errors 6.12±4.2 5.28±4.32 
    failure to maintain the set 0.7±2.21 0.6±1.57 
    global score 18.34±21.53 11.48±21.17 
State and Trait Anxiety Inventory–Y   
    state 49.6±8.59 51.6±11.38§ 
    trait 50.1±9.08§ 53.2±8.5§ 
Beck Depression Inventory 12.3±7.33§ 14.2±7.56§ 
Epworth scale 5.3±2.7 4.9±3.1 
Activities of daily living (ADLs) 5.6±0.69 4.8±1.31 
Instrumental activities of daily living (IADLs)  5.2±1.61 4.1±2.07* 
Unified Multiple System Atrophy Rating Scale (UMSARS)  19.8±4.54 28.3±6.91* 
* p<0.05; § pathological score 
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Table 5. Video-polysomnographic recordings at T0 
 
 
 
Sleep parameters Pt. 1 Pt. 2 Pt. 3 Pt. 4 Pt. 5 Pt. 6 Pt. 7 Pt. 8 Pt. 9 Pt. 10 mean±s.d. 
            
Total sleep time 
(min) 312 249 341 293 194 291 283 335 343 215 285.6±51.96 
Sleep efficiency 
(%) 82 79 87 75 49 67 70 83 79 56 72.7±12.3 
Phase            
    1 (%) 4 5 3 6 6 20 7 2 16 3 7.2 
    2 (%) 40 43 27 72 35 56 56 42 51 41 46.3 
    3 (%) 19 14 38 14 41 12 18 5 11 42 21.4 
    REM (%) 37 38 32 9 18 12 19 51 22 14 25.2 
WASO (%) 13 18 11 23 48 30 22 17 21 43 24.6 
Sleep latency 
(min) 24 14 10 15 25 22 47 2 2 12 17.3±13.22 
REM latency 
(min) 74 95 56 140 120 135 114 67 21 254 107.6±63.7 
PLMS index 79 191 11 10 105 134 10 101 5 6 65.2±66.47 
Arousal index 7 6 7 20 7 6 8 13 10 6 9±4.44 
Apnea index   0 0 3 8 6 3 11 8 50 1 9±14.88 
SaO2  (min – max) 93 - 99 80 - 98 92 - 97 91 - 98 90 - 95 94 - 97 90 - 96 91 - 95 81 - 98 91 - 99 89.3 – 97.2  
